volunteer partners client login explore parexel journeygo solutionsgo experiencego planningphase iphase iiaphase ii iiiphase iiib ivpost launch clinical researchearly phase servicesdedicated therapeutic expertiseearly phase and late phase integrated study managementpatient populationsstrategic locationsberlinvirtual tourlondonvirtual tourbaltimorefacilityvirtual tourlos angelesvirtual tourbloemfonteinfacilityvirtual tourphase 1 first in humanethnobridging for accelerated global drug developmentphase iia proof of conceptearly product developmentethnobridgingclinical pk pd and pharmacometrics servicescase study safety pharmacovigilance 1case study safety pharmacovigilance 2bioanalytical and biomarkersbioequivalence studiesvolunteer to participatephase ii iii servicesphase iiicase study chronic renal failurecase study expanded access programcase study accelerating development in global copd trialsmedical writing and submissionfeasibility and enrollmentpatient recruitmentcase study pediatric migraine patient recruitmentcountry and site selectionalliance site strategyprotocol optimizationphase iiib ivquantitative clinical development servicesclinical development optimizationdata surveillancesite regulatory documentationcritical path managementclinical adjudicationclinical trial supplies & logisticsglobal reachclinical trial suppliesancillary supplieslaboratory logistics servicesrandomization and trial supply managementcold chain logisticsclinical trial supply chain active trackingcustomer care servicesgenomic medicine servicesinformaticsperceptive mytrials data driven monitoringcombined edc rtsmeclinical metricscollaboration toolboxintegration servicesperceptive mytrials platform and infrastructureperceptive mytrials analyticsstudy management and monitoringimpact ctms softwareimpact ctms supportimpact progressimpact mysitesimpact investigatorimpact clinical cost trackingimpact clinical supplies trackingrisk based monitoringclinical leader interview with camie britonelectronic data capturedatalabs edcedc ranked highest in customer satisfactiontaking the pain out of edc deploymentdatalabs edc trainingrandomization and trial supply managementclinphone rtsm for early phaseclinphone rtsm for phase ii iiifaster implementation of rtsm a.k.a. irt systemsdrug accountabilityadaptive trialsreporting solutionsclinphone rtsm for peri post approvalclinphone rtsm for asia pacificclinical trial supplies & logisticsclinical trial supply chain active trackingpulmonary function testingmedical imagingtherapeutic expertiseoncology imaging expertisecriteria experience1996 nci wg clliwcll 2008key topics iwcll 2008definitionsusable criteria to evaluatetarget sites of diseasenon target sites of diseaseorganomegalynew lesionsb symptomsblood countsbone marrowtransformationrole of imaging in cll clinical trialsclinical data assessments1999 iwg nhl2007 iwg nhlkey topics 2007 iwg nhl assessment criteriadefinitionsusable criteria to evaluatetarget sites of diseasenon target sites of diseaseorganomegalynew lesionsbone marrowother laboratory values and symptomsincorporation of fdg petdefining normal abnormal and measurableproblem with crurecistrespiratory and pulmonology imaging expertiseophthalmology imaging expertisegastroenterology imaging expertisedermatology imaging expertisewomen s health imaging expertisemusculoskeletal msk imaging expertiseneurology imaging expertisevolumetric imaging expertisecardiovascular imaging expertiseimaging servicesscientific advisorsconsultationadvanced medical imagingcloud based solutions for sitesregulatory information managementliquent insight regulatory cloudregulatory outsourcing servicescustomer care servicesparexel s education servicesdatalabs edc trainingperceptive mytrials trainingdata driven monitoring trainingcertification programsimpact ctms trainingother training servicesliquent insight education servicesabout trainingtypes of trainingcourses & registrationliquent insight for submission managementliquent insight submission planning and trackingliquent smartdesk automating the publishing process with liquent smartdesk for pdfliquent insight for viewingreviewing submissions with liquent insight for viewingtraining resourcescertificationelectronic clinical outcome assessments ecoa epro electronic patient reported outcomes clinical outcome assessments consultingasset transfer servicesconsultingintegrated product developmenta biosimilar milestone with implicationsregulatory compliance & risk managementq & a about gcpquality by design putting theory into practicestrategic compliance data integrityfda 483s your questions answeredimportant reminder about pet positron emitting topography fda regulationsquality by design putting theory into practiceregulatory outsourcing servicesectdregulatory information management & idmp solutionsidmp readiness assessmentidmp task force updatesnovember 2015 task force meetingcustomer care servicesaccesslate stage clinical operationslate phase interventional trialsobservational researchepidemiologyexpanded access programspatient reported outcomescase study health economicsoutcomes researchmarket access consultingcommercial decision pathwaysevidence generationevidence review and meta analysisevidence review optionsevidence review resourceshealth economic modelingglobal and amcp value dossiersmanuscripts and postersdata analyticsstrategic communicationsaccess realizationpricing reimbursement and market access expertiselist of services pricing reimbursement and market accessmarket access and hub servicesdrug safety servicesrisk management remsmedical communicationscommunications planning & publications programsscientific clinical & health economic writingkol advisoryclinical communicationscreative strategydigital mediaglobal meetings & events managementpayer communicationseditorial and production servicesreal world evidencereal world data webinar therapeutic expertiseoncologycardiovascular & metabolic diseasescentral nervous system cns disordersinfectious diseaserespiratory capabilitiesrheumatology & immunology capabilitiesindustry expertisepharmaceuticalsbiosimilar consultingmedical devicesbiologicsbiosimilarsbiosimilar videoregulatory expertisemarket access expertiseglobal presencenorth americasouth americaeuropeasiamiddle east & africaemerging marketsdelivery modelsstrategic partnershipsessential building blocks for successful strategic partnershipsfunctional servicesdedicated to your successparexel biopharm unit about news & events investors careers countries contact us volunteer partners client login journeyplanningphase iphase iiaphase ii iiiphase iiib ivpost launchsolutionsclinical researchearly phase servicesphase ii iii servicesphase iiib ivquantitative clinical development servicesclinical development optimizationclinical trial supplies & logisticscustomer care servicesgenomic medicine servicesinformaticsperceptive mytrials study management and monitoringelectronic data capturerandomization and trial supply managementpulmonary function testingmedical imagingregulatory information managementcustomer care servicesparexel s education serviceselectronic clinical outcome assessments ecoa asset transfer servicesconsultingintegrated product developmentregulatory compliance & risk managementregulatory outsourcing servicesregulatory information management & idmp solutionscustomer care servicesaccesslate stage clinical operationsmarket access consultingdrug safety servicesmedical communicationsreal world evidenceexperiencetherapeutic expertiseoncologycardiovascular & metabolic diseasescentral nervous system cns disordersinfectious diseaserespiratory capabilitiesrheumatology & immunology capabilitiesindustry expertisepharmaceuticalsmedical devicesbiologicsbiosimilarsregulatory expertisemarket access expertiseglobal presencenorth americasouth americaeuropeasiamiddle east & africaemerging marketsdelivery modelsstrategic partnershipsfunctional servicesparexel biopharm unitcompanymanagement teamjosef h. von rickenbachmark a. goldberg m.d.roland andersson ph.d.douglas a. battxavier flinoisdavid j. godwinmichelle grahamsy pretorius m.d.emma reevegadi saaronyjoshua schultznews & eventspress releaseseventswebinars12th annual partnerships in clinical trials congressarchived parexel in the newsfind an officeinvestorscareerscareers at parexel ceo messagefind your path opportunitiesuniversity graduates opportunities for studentsvolunteerabout uslocations worldwideabout clinical trialswhy participate faqsglossarysustainabilityconsumption trend analysiscode of conducteclinical innovationpurchasingpurchase order terms and conditionsbedingungen f r den kaufauftragvigente desde elpo terms japanesepo terms chinese s po terms chinese t ordem de compra termos e condi escontact usthank youpartnersservice partnerstraining partnerstechnology partnersreferral partnersaccredited partner programperceptive user group meetingimpact ctms user group meeting details and agendasimpact ctms user group meeting justification lettermeeting registration and hotel detailsbenefits for attending the impact ctms user group meetingregistration rateshotel ratesgraduateparexel insightshigh performance workplace practices that attract and retain millennialsincreasing study predictabilitymergers & acquisitions where s the real finish line navigating regulatory submissionsinterview with parexel s aida sabo about challenges & successes in diversity & inclusionutilizing secondary healthcare data assetsoptimizing the clinical development process with social mobile analytics and cloud smac training compliance is an increasingly complex journeybeyond diversity what happens when you define a culture of inclusionthe next generation of talent management opportunities for diversityget into pole position with modern irt serviceswhen it comes to ctms one size does not fit allprotocol optimizationusing analytics to optimize the clinical development processshogo nakamori discusses joint program for clinical researchjosh schultz corp. vp talks about parexel accessnew approaches to data management in clinical trialsshogo nakamori discusses japan & multi national trialsshogo nakamori discusses trends in drug development in japaninvolved & engaged the last mile of business performancewhy rtsm & irt stand for speed simplicity & servicedream or reality improving patient safety & reducing costs drew garty discusses data driven monitoringalbert liou discusses the drug development landscape in korearoland andersson svp discusses investing trends and emerging biopharmaceutical companiesmark a. goldberg president & coo discusses parexel s acquisition of quantum solutions india qsi albert siu phd explains how parexel academy benefits clientsubavka denoble talks about parexel s biopharm unitdr . sy pretorius chief scientific officer talks about adaptive design trialsparexel s training approach and the importance of training a global workforceclinical trial support query who ya gon na call 3 examples of breakthrough analytics at dia china social media recruitment & monitoringclinical trial feasibility & patient enrollment differentiation through innovationinnovation in the pharmaceutical industry a change toward personalized medicinea biosimilar milestone with implicationsdesigning trials payers can trustthe human touch aligning reward systems with company strategy and meaningful workdiversity and inclusion this is how the best global companies learn plan and measure successaccelerated pathways and stock pricesaccelerated pathways & commercial consequences forum & findingsaccelerated pathways global opportunities & challenges for innovators now is the time to include japan says parexela people strategy attracts the best talentthree keys to mitigating risk in adaptive trialshow to know you re keeping your clinical trial supplies cooladaptive trials complex but advantageousagile irtagile irtreduced timelinessimpler processesexpert servicescontacttestaccess hubputting the real in real world evidencehow to engage external partners to gain market access3 important considerations of cardiovascular outcomes trialsthree steps for filling real world evidence gapsreal world evidence of treatment pattern and costs of fibromyalgianot ready for the real world a hybrid approach to post approval researchoptimize data collection in prospective study designsfda s accelerated pathways are the new normalplaying defense in a riskier commercial environment for cancer drugsthe rise of indication specific pricing in the uk three drug development habits to mitigate commercial riskstrengthen your product value story one phase at a timecommercial consequences of expedited approval5 benefits of building a robust evidence platforminnovation in real world researchaccelerated pathways global opportunities and challenges for innovatorsno nice now what 3 steps to a successful expanded access programan integrated pharmacovigilance model to meet regulatory trendsdiscussion on hybrid study design at dia 2016differences in hta acceptance rates across disease areasunlocking the value of observational researchbe a step ahead at every stepwalking feetnothing costs more than failurereal world data strategiesan alternative route to market access in scotland how to meet the needs of stakeholdersclient oversight benefits of a 1 15 ratiolate phase partnershipsdoes practice make perfect organizing internally for external value communicationshow to increase the impact of observational researchincreasing the impactwebinar how to develop a global observational studypharmacovigilance knowledge process outsourcing kpo how to prove comparative valuecracking the codecase study database solutionsachieving global value from local observational researchcase study metabolic disease observational studycase study expanded access programnon adherence in chronic myeloid leukemiacase study commercialization strategylate phase successlate phase success videocase study rapid recruitmentspanish therapeutic positioning reportsexpanded access program navigating the when who and howprice globally . negotiate locally.case study site identification & qualificationcase study complex data collectionhow to prepare for product commercializationhow to build a study global value dossierhow to use market access data for successful product launchunderstanding data driven monitoringdelivering data that supports your value argumentproduct approval demands real world evidencewhat is the value of a qaly how to design a trial payers can trustcost effectiveness modellingnon adherence in patients with breast cancer a systematic reviewearly economic models pay offthe path to better clinical trial designfive steps to winning market sharethe importance of building value with real world dataare the smc getting nicer price optimization a global strategy for local marketsbringing drugs to market earlydiscover how our teams work together for a bigger picturepaint by fishhow to build a robust argument of valuecomparative effectiveness research are we there yet how to use evidence based prioritizationnew science demands real world dataregulatory portalregulatory librarya smart global regulatory submissions strategy is flexible nuanced and nails the logisticsfda s accelerated pathways are the new normalvideo how similar is biosimilar us versus eutop 3 mistakes to avoid when responding to an fda form 483strategic regulatory considerations for early medical device consultations with global regulatory authoritiesa smart global regulatory submissions strategy is flexible nuanced and nails the logisticsselecting a regulatory outsourcing partnerregulatory outsourcing preparing for the partnershipvideo navigating regulatory submissionsaccelerating global submissions with a six point ectd strategythe eu s falsified medicines directive and apispodcast 5 ways to detect data integrity mistakespodcast 5 ways to prevent data integrity mistakesvideo parexel s liquent smartdesk for authoring the opportunities and pitfalls of seeking early scientific advice in the euearly stage haste creates future waste three strategies that integrate your value storyshogo nakamori discusses trends in drug development in japanthe indian biosimilars guidelinescommercial consequences of expedited approvalinnovation in the pharmaceutical industry a change toward personalized medicineaccelerated pathways & commercial consequences forum & findingsestablishing us approvals for biosimilarsq & a about gcpthe role of quality data in demonstrating biosimilarity to a reference biologic5 ways to streamline biosimilar developmenttop 5 misconceptions aout data integritybook assuring data integrity for life scienceslatest idmp task force update to inform timing strategy and operational planning website idmpidmp readiness assesmentliquent insight brochurestrategies to reduce phase iii failure ratessiegfried schmitt reviews us and eu internal audit requirement compliance issues in industry publicationsbook quality by design putting theory into practiceregulatory coming soon menu home the ability to recognize what lies ahead simplifies . watch the video journey solutions experience x the first steps of any journey include choosing the smartest route to your destination . to do that well start by choosing the industry leadership and global resources of parexel . explore planning x to simplify your journey from new molecules to new medications start with a partner who ll be beside you at every step with expertise technologies and facilities worldwide . explore phase i x by accelerating your access to the right patients and expertise for your journey we accelerate your access to the efficacy data you need to persuade key stakeholders . explore phase iia x while our strategic